C-SRC protein tyrosine kinase regulates early HIV-1 infection post-entry

AIDS

Volumn 30, Issue 6, 2016, Pages 849-857

  McCarthy, Stephen D S ^a   Sakac, Darinka ^b   Neschadim, Anton ^a,b   Branch, Donald R ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

c SRC; CD4+T cells; HIV 1; HIV 1 inhibition; kinase inhibitors; protein tyrosine kinase 2 beta; repurposing drugs; tyrosine kinase

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DASATINIB; GAG PROTEIN; KX 2 391; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 2 BETA; PROTEIN TYROSINE KINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; SARACATINIB; SMALL INTERFERING RNA; SRC INHIBITOR 1; UNCLASSIFIED DRUG; FOCAL ADHESION KINASE 2; PROTEIN KINASE INHIBITOR; PTK2B PROTEIN, HUMAN;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN HXB2); HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN R5); HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN X4); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIFE CYCLE; LONG TERMINAL REPEAT; LUCIFERASE ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; CELL CULTURE; GENE SILENCING; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PHYSIOLOGY; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FOCAL ADHESION KINASE 2; GENE KNOCKDOWN TECHNIQUES; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 84960447330     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001028     Document Type: Article

References (42)

1. Bertoletti F, Crespan E, Maga G. Tyrosine kinases as essential cellular cofactors and potential therapeutic targets for human immunodeficiency virus infection. Cell Mol Biol (Noisy-le-Grand) 2012; 58: 31-43.
2. Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 2014; 28: 325-334.
3. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Path 2014; 10: e1004071.
4. Desimmie BA, Schrijvers R, Demeulemeester J, Borrenberghs D, Weydert C, Thys W, et al. LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology 2013; 10: 57.
5. Shan L, Xing S, Yang HC, Zhang H, Margolick JB, Siliciano RF. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-Transduced primary resting CD4R T cells. J Antimicrobiol Chemother 2014; 69: 28-33.
6. Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, Siani MA, et al. Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 1997; 186: 1793-1798.
7. Readinger JA, Schiralli GM, Jiang JK, Thomas CJ, August A, Henderson AJ, et al. Selective targeting of ITK blocks multiple steps of HIV replication. Pro Natl Acad Sci USA 2008; 105: 6684-6689.
8. Harmon B, Campbell N, Ratner L. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a posthemifusion step. PLoS Path 2010; 6: e1000956.
9. Bukong TN, Hall WW, Jacque JM. Lentivirus-Associated MAPK/ERK2 phosphorylates EMD and regulates infectivity. J Gen Virol 2010; 91: 2381-2392.
10. Gallay P, Swingler S, Aiken C, Trono D. HIV-1 infection of nondividing cells: C-Terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 1995; 80: 379-388.
11. Phipps DJ, Read SE, Piovesan JP, Mills GB, Branch DR. HIV infection in vitro enhances the activity of src-family protein tyrosine kinases. AIDS 1996; 10: 1191-1198.
12. Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, et al. Long-Term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study. Blood 2014; 123: 2317-2324.
13. Pogliaghi M, Papagno L, Lambert S, Calin R, Calvez V, Katlama C, et al. The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4R T cells from HIV-1 infected patients. AIDS 2014; 28: 278-281.
14. Collins M, Bartelt RR, Houtman JC. T cell receptor activation leads to two distinct phases of Pyk2 activation and actin cytoskeletal rearrangement in human T cells. Mol Immunol 2010; 47: 1665-1674.
15. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999; 71: 435-478.
16. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 1996; 383: 547-550.
17. McCarthy SD, Jung D, Sakac D, Branch DR. c-Src and Pyk2 protein tyrosine kinases play protective roles in early HIV-1 infection of CD4R T-cell lines. J Acquir Immune Defic Syndr 2014; 66: 118-126.
18. Seror C, Melki MT, Subra F, Raza SQ, Bras M, Saïdi H, et al. Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J Exp Med 2011; 208: 1823-1834.
19. Gilbert C, Barat C, Cantin R, Tremblay MJ. Involvement of Src and Syk tyrosine kinases in HIV-1 transfer from dendritic cells to CD4R T lymphocytes. J Immunol 2007; 178: 2862-2871.
20. Manganaro L, Lusic M, Gutierrez MI, Cereseto A, Del Sal G, Giacca M. Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4R T lymphocytes. Nat Med 2010; 16: 329-333.
21. ODoherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol 2002; 76: 10942-10950.
22. Yamamoto N, Tanaka C, Wu Y, Chang MO, Inagaki Y, Saito Y, et al. Analysis of human immunodeficiency virus type 1 integration by using a specific, sensitive and quantitative assay based on real-Time polymerase chain reaction. Virus Genes 2006; 32: 105-113.
23. Schmittgen TD, Livak KJ. Analyzing real-Time PCR data by the comparative C (T) method. Nature Protoc 2008; 3: 1101-1108.
24. Pizzato M, Erlwein O, Bonsall D, Kaye S, Muir D, McClure MO A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. J Virol Methods 2009; 156: 1-7.
25. Vermeire J, Naessens E, Vanderstraeten H, Landi A, Iannucci V, Van Nuffel A, et al. Quantification of reverse transcriptase activity by real-Time PCR as a fast and accurate method for titration of HIV, lenti- And retroviral vectors. PloS One 2012; 7: e50859.
26. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
27. Harvey R, Hehir KM, Smith AE, Cheng SH. pp60c-src variants containing lesions that affect phosphorylation at tyrosines 416 and 527. Mol Cell Biol 1989; 9: 3647-3656.
28. Collins M, Tremblay M, Chapman N, Curtiss M, Rothman PB, Houtman JC. The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402 and 580 occurs via a distinct mechanism than other receptor systems. J Leukoc Biol 2010; 87: 691-701.
29. Bukrinsky M, Sharova N, Stevenson M. Human immunodeficiency virus type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. J Virol 1993; 67: 6863-6865.
30. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PloS One 2010; 5: e11160.
31. Tyler T. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. Ann Pharmacother 2009; 43: 920-927.
32. Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, et al. Synergy of entry inhibitors with direct-Acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 2015; 64: 483-494.
33. de Wispelaere M, LaCroix AJ, Yang PL. The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol 2013; 87: 7367-7381.
34. Marzia M, Chiusaroli R, Neff L, Kim NY, Chishti AH, Baron R, et al. Calpain is required for normal osteoclast function and is down-regulated by calcitonin. J Biol Chem 2006; 281: 9745-9754.
35. Bartelt RR, Cruz-Orcutt N, Collins M, Houtman JC. Comparison of T cell receptor-induced proximal signaling and downstream functions in immortalized and primary T cells. PloS One 2009; 4: e5430.
36. Rato S, Chiusaroli R, Neff L, Kim NY, Chishti AH, Baron R, et al. Novel HIV-1 knockdown targets identified by an enriched kinases/phosphatases shRNA library using a long-Term iterative screen in Jurkat T-cells. PloS One 2010; 5: e9276.
37. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008; 135: 49-60.
38. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008; 4: 495-504.
39. Francis AC, Di Primio C, Allouch A, Cereseto A. Role of phosphorylation in the nuclear biology of HIV-1. Curr Med Chem 2011; 18: 2904-2912.
40. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013; 208: 1436-1442.
41. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460-465.
42. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-650.